Related Experiment Video
Updated: Jul 18, 2026
07:28
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
Inhaled insulin (Exubera): Combining efficacy and convenience
Srikanth Bellary1, Anthony H Barnett
1Department of Medicine-Undergraduate Centre, Heart of England NHS Foundation Trust, Birmingham, UK.
Diabetes & Vascular Disease Research
|December 13, 2006
Summary
Inhaled insulin offers a convenient alternative to injections for diabetes management. This new pulmonary drug delivery method shows effectiveness and safety, potentially improving treatment adherence and glycemic control.
Area of Science:
- Pulmonary drug delivery
- Peptide bioavailability
- Diabetes management
Background:
- The pulmonary route is advantageous for drug delivery due to its vascularity and large surface area.
- Previous peptide delivery via inhalation faced bioavailability challenges.
- Technological advancements have enabled new pulmonary delivery devices.
Purpose of the Study:
- To evaluate the efficacy and safety of inhaled insulin as a novel peptide delivery method.
- To assess patient convenience and treatment adherence compared to subcutaneous insulin injections.
- To explore the potential of inhaled insulin in improving glycemic control for diabetic patients.
Main Methods:
- Development of novel pulmonary delivery devices for peptide therapeutics.
- Clinical trials assessing inhaled insulin (Exubera) efficacy and safety.
- Comparison of inhaled insulin with traditional subcutaneous meal-time insulin injections.
Main Results:
- Inhaled insulin (Exubera) has been approved for clinical use.
- Clinical trials demonstrate inhaled insulin to be effective and safe.
- Inhaled insulin is a preferred alternative to subcutaneous injections for meal-time insulin therapy.
- The new technology offers significant convenience for patients requiring insulin treatment.
Conclusions:
- Pulmonary delivery of insulin represents a significant advancement in diabetes care.
- Inhaled insulin can reduce the number of daily injections, potentially encouraging earlier insulin initiation.
- Improved patient adherence and enhanced glycemic control are significant potential benefits of this new delivery method.
Related Concept Videos
01:27Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:23Inhaled Medications
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:25Insulin: Biosynthesis, Chemistry, and Preparation
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...